Start the program by clicking on the Start Program icon at the bottom of this page.
|
| Program Title |
 |
|
Combination Radiation and Chemotherapy: Targeting Therapy for Newly Diagnosed Glioblastoma
Release Date: January-15-10
Credit Expiration Date: January-15-11
|
|
|
 |
| Program Developer/Facilitator |
 |
|
Medical Communications Media, Inc. |
|
|
|
| Target Audience |
|
|
| This educational activity is designed to meet the needs of neurosurgeons, neuro-oncologists, radiation oncologists, medical oncologists, and other healthcare providers interested in the treatment of primary gliomas. |
|
|
|
| Credit Hours |
|
|
|
|
|
| Medium |
|
|
|
|
|
| Program Description |
|
|
| Based on strong evidence, combination therapy with radiation and temozolomide is widely prescribed and currently considered the standard treatment for patients with newly diagnosed glioblastoma. Still, some tumors are resistant to combination therapy. Subsequently, trials studying varying strategies to overcome resistance, such as dose-dense regimens and adding targeted therapies, are being conducted. Additional trials are assessing the effectiveness of combination therapy strategies on recurrent glioblastoma. |
|
|
|
| Learning Objectives |
|
|
|
|
|
| Faculty |
|
|
Katsuyuki Shirai, MD, PhD
Postdoctoral Researcher
Arthur G. James Comprehensive Cancer Center and
Richard L. Solove Research Institute
Ohio State University Medical School
Columbus, OH
Arnab Chakravarti, MD
Chair and Professor, Department of Radiation Oncology
Max Morehouse Chair of Cancer Research
Co-Director, Brain Tumor Program
Arthur G. James Comprehensive Cancer Center and
Richard L. Solove Research Institute
Ohio State University Medical School
Columbus, OH
|
|
|
|
| Disclosures |
|
|
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Dr. Chakravarti discloses that he serves on the speakers’ bureau of Schering-Plough and is a consultant for Genentech.
Dr. Shirai has no relevant financial conflicts to disclose. |
|
|
|
| Commercial Support Statements |
|
|
This activity is supported by an educational grant from Schering-Plough Corporation. |
|
|
|
|
|
| Credit Statements |
|
|
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians. |
|
|
AKH Inc. designates this educational activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
|
|
|
|
|
| Instructions |
|
|
|
|
|
| Certificate Fee |
|
|
|
|
|
| Disclaimer |
|
|
| © 2010. All rights reserved. None of the contents of this publication may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication are those of the faculty members and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Schering-Plough Corporation. Any medications, diagnostic procedures, or treatments discussed by the faculty members should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities. |
|
|
| |
